Form 144 ALNYLAM PHARMACEUTICALS For: 2 October By Investing.com
This article announces the filing of Form 144 for ALNYLAM PHARMACEUTICALS on October 2. Form 144 is filed by individuals who intend to sell restricted or controlled securities. The article briefly mentions other popular news items and provides stock market data.
Form 144 ALNYLAM PHARMACEUTICALS For: 2 October
This article reports on a Form 144 filing for ALNYLAM PHARMACEUTICALS (ALNY) dated October 2. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates the company's stock symbol as ALNY and notes a current price change of -4.96%.
An Alnylam (ALNY) officer proposes a $399K share sale that includes shares to cover an equity-award tax bill.
Alnylam Pharmaceuticals, Inc. (ALNY) officer Bryan A. Supran has proposed selling 1,758 common shares, valued at approximately $398,862.25, on October 2, 2026. The sale is intended to cover a tax obligation arising from the settlement of a vested equity award distribution. The shares were acquired through restricted-stock vesting on October 1, 2026.
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
Alnylam Pharmaceuticals' stock has fallen by 49% over the past year, prompting questions about its valuation relative to its earnings. The company currently trades at a P/E ratio of 39.9x, which is significantly higher than both the biotech industry average and its peer group, suggesting it may be overvalued based on current earnings. Analysts are debating whether future profitability and pipeline developments can justify the current market price, with some community narratives suggesting it could be undervalued.
Here's How Much $100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has significantly outperformed the market over the last 20 years, achieving an average annual return of 14.01%. An initial investment of $100 in ALNY stock two decades ago would now be worth $1,402.11, demonstrating the power of compounded returns. The company currently holds a market capitalization of $31.50 billion.
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)
This article summarizes recent analyst ratings for three healthcare companies: Alnylam Pharma (ALNY), AxoGen (AXGN), and Biohaven Ltd. (BHVN). Cantor Fitzgerald maintained a Hold rating for Alnylam Pharma, while Canaccord Genuity maintained Buy ratings for both AxoGen and Biohaven Ltd. The article provides price targets and analyst success rates for each company.
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
This article highlights four RNA therapeutics companies – Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Wave Life Sciences, and Arcturus Therapeutics – that are at the forefront of innovation in RNA medicine. These companies utilize various RNA technologies like RNAi, antisense, RNA editing, and mRNA to develop treatments for a wide range of diseases including cardiometabolic, neurological, and rare disorders. The article details each company's commercial products, clinical pipeline, and recent financial performance, emphasizing their potential for continued growth in the expanding field of RNA therapeutics.
Form 4 Alnylam Pharmaceuticals Inc For: 27 September By Investing.com
This article reports on a Form 4 filing for Alnylam Pharmaceuticals Inc (ALNY) on September 27, 2026. The Form 4 filing is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders. The article indicates a 2.55% change for ALNY.
Form 4 Alnylam Pharmaceuticals Inc For: 27 September
This article reports on a Form 4 filing by Alnylam Pharmaceuticals Inc. for September 27. It appears to be a placeholder or automated notice, as the content primarily consists of general market data and news headlines, with no specific details about the Form 4 filing itself. The article highlights Alnylam Pharmaceuticals Inc. (ALNY) and its stock performance.
Cambridge biotech co-founded by Alnylam founder Maraganore files for IPO
City Therapeutics, an RNAi biotech co-founded by Alnylam founder Maraganore, has filed for an initial public offering (IPO) on Nasdaq under the ticker CTY. The company, which has raised approximately $238.8 million since its launch in October 2024, currently employs 81 people and has established partnerships with Bausch + Lomb and Biogen. The IPO aims to build on the success of Alnylam Pharmaceuticals Inc.
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $455
H.C. Wainwright has reiterated its Buy rating for Alnylam Pharmaceuticals (ALNY.US) and maintained a target price of $455. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and valuation.
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals has updated its 2026 TTR franchise revenue outlook to $4.2 billion–$4.5 billion, reflecting a shift in market mix towards 80% first-line and 20% second-line use for AMVUTTRA. Despite the revision, the company emphasizes strong market fundamentals with many undiagnosed patients and upcoming pipeline catalysts in Huntington's disease, obesity, and bleeding disorders. Alnylam also noted that AMVUTTRA's deep TTR knockdown and quarterly dosing contribute to its market momentum.
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
Alnylam Pharmaceuticals is advancing zilebesiran, an investigational RNAi therapy for uncontrolled hypertension with high cardiovascular risk, targeting sustained blood pressure control with twice-yearly injections. The Phase III ZENITH trial is enrolling 11,000 high-risk patients globally to assess if zilebesiran reduces cardiovascular events compared to standard care, with Alnylam aiming for a 15-20% reduction in major adverse cardiovascular events. This therapy aims to address the significant global burden of hypertension and challenges with adherence to daily oral medications.
Alnylam at Wells Fargo conference: TTR growth stays on track
Alnylam Pharmaceuticals discussed the strength of its transthyretin amyloidosis (TTR) business at the Wells Fargo 21st Annual Healthcare Conference, highlighting that the franchise achieved over $1 billion in quarterly revenue. Despite this milestone, the company reset its 2026 guidance due to the normalization of second-line patient inflows and international pricing pressures. Alnylam also detailed pipeline progress in Huntington's disease and bleeding disorders, emphasizing the broad access and competitive advantages of its AMVUTTRA treatment.
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Alnylam Pharmaceuticals announced that its management will present company overviews at two upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference. Live audio webcasts and replays of these presentations will be available on the Investors section of Alnylam's website. The company, a pioneer in RNAi therapeutics, continues to focus on developing transformative therapies and expanding its robust pipeline.
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Oppenheimer has reiterated its Outperform rating on Alnylam Pharmaceuticals (ALNY) with a $350 price target, following the release of new data that reinforces the potential of Nucresiran and the TRITON-CM study. This positive outlook comes despite recent adjustments to Alnylam's price target by Oppenheimer and RBC, and a cut in its 2026 net product revenue guidance. The company, which specializes in RNA interference technology, reported mixed Q2 2026 results but continues to advance its pipeline in treating rare and chronic diseases.
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR
Alnylam Pharmaceuticals announced new data at the ESC Congress 2026, reinforcing the efficacy of its RNAi therapeutics, AMVUTTRA (vutrisiran) and zilebesiran, for cardiovascular diseases. The data highlighted AMVUTTRA's consistent clinical benefits in ATTR-CM patients, even those on tafamidis, and its positive impact on multisystemic manifestations. Additionally, new subgroup analysis for zilebesiran demonstrated potential for enhanced blood pressure control in uncontrolled hypertension.
Alnylam stock maintained at Buy by Truist on mixed trial data
Truist Securities has reiterated a Buy rating and a $315.00 price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) despite mixed trial data from a competitor's CARDIO-TTRansform trial. The firm noted potential positive implications for Alnylam's Amvuttra and nucresiran, but also highlighted lingering questions regarding the future treatment landscape for TTR-CM and the optimization of Alnylam's TRITON-CM trial. Other analysts from TD Cowen, BMO Capital, and Canaccord Genuity also maintained Buy/Outperform ratings, emphasizing the strength of Alnylam's TTR silencing therapies.
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
This article discusses the hypothetical return on an investment of $100 in Alnylam Pharmaceuticals stock made 20 years ago. It calculates the significant growth this initial investment would have seen, illustrating the potential for long-term gains in the stock market.
Alnylam Pharmaceuticals (ALNY) Stock Looks Cheap After A 47% Fall Yet Rich On Earnings
Alnylam Pharmaceuticals (ALNY) has seen a significant 46.8% fall in its stock price over the past year, making it appear cheap. However, its valuation, particularly its P/E ratio of 40.8x, suggests it is still expensive compared to industry averages and its calculated fair P/E of 32.4x. Investors are looking to upcoming clinical data at the ESC Congress 2026 for AMVUTTRA and zilebesiran to see if these can justify the premium valuation despite recent weaker returns.
Alnylam (ALNY) Stock May Look Rich On Earnings Despite Weaker Price Action
Alnylam Pharmaceuticals (ALNY) has seen a significant stock price decline of 46.8% over the past year, yet its current valuation still appears expensive based on earnings. The company's P/E ratio of 40.8x is higher than the biotech industry average, suggesting investors are paying a premium despite upcoming clinical data potentially impacting sentiment. The article questions whether future earnings can justify this premium or if the market will adjust expectations.
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP has initiated an investigation into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) following a significant drop in its stock price. This investigation comes after Alnylam announced disappointing Q2 2026 financial results, lowering its full-year TTR product sales guidance by approximately $200 million. The company's stock subsequently fell over 28%, leading to potential federal securities law violations on behalf of investors.
Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Silvant Capital Management LLC has acquired a new position of 18,126 shares, valued at $5.46 million, in Alnylam Pharmaceuticals. This comes as Alnylam reported strong Q2 earnings per share, surpassing consensus estimates, though revenue slightly missed expectations. Analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $386.62, despite recent downward revisions from some firms and a 5.5% drop in share price at opening.
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors E
Kirby McInerney LLP is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. following a significant drop in its stock price. This decline occurred after Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to a normalization of growth in the ATTR-CM market. Investors who purchased Alnylam securities are encouraged to contact Kirby McInerney LLP to discuss their rights.
Lowered TTR Sales Outlook And Legal Probe Might Change The Case For Investing In Alnylam (ALNY)
Alnylam Pharmaceuticals recently cut its 2026 full-year TTR product sales guidance due to reassessed growth expectations for the ATTR-CM market. This reduction in sales outlook, coupled with an ongoing legal investigation into potential federal securities law violations, introduces uncertainty for investors. The developments highlight Alnylam's dependence on TTR demand and may influence its valuation.
Bragar Eagel & Squire, P.C. is Investigating Alnylam
Bragar Eagel & Squire, P.C. announced an investigation into Alnylam Pharmaceuticals, Inc. on behalf of its stockholders. The investigation follows a significant drop in Alnylam's stock price after the company lowered its full-year 2026 TTR product sales guidance due to slower-than-expected growth in the ATTR-CM market. The law firm is encouraging investors who suffered losses to contact them regarding potential claims of federal securities law violations.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, causing its stock to drop significantly. The firm is urging shareholders who lost money to contact them to potentially pursue claims. The investigation focuses on whether Alnylam violated federal securities laws.
E Fund Management Co. Ltd. Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
E Fund Management Co. Ltd. has acquired a new stake of 6,073 shares in Alnylam Pharmaceuticals, Inc. valued at approximately $1.83 million during the second quarter. Institutional investors collectively own 92.97% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $386.62 despite some target reductions. Alnylam Pharmaceuticals reported strong Q2 earnings per share of $1.84, exceeding expectations, with revenue up 66.9% year-over-year to $1.29 billion.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) regarding potential violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where they lowered their full-year 2026 TTR product sales guidance, resulting in a significant drop in stock price. Shareholders who incurred losses are encouraged to contact the firm to inquire about potentially pursuing a claim.
NewEdge Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
NewEdge Advisors LLC significantly reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 82.2% in the first quarter, selling over 10,000 shares. Despite this reduction, institutional ownership remains high at nearly 93%, with several major investors increasing their positions. Alnylam Pharmaceuticals reported strong Q1 earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating for the stock.
ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Kirby McInerney LLP is investigating potential securities law violations by Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) following a significant drop in stock price. This decline occurred after Alnylam lowered its full-year 2026 TTR product sales guidance by approximately $200 million due to evolving market conditions. Investors who purchased Alnylam securities are encouraged to contact the law firm to learn more about their rights.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for possible violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where they lowered their TTR product sales guidance for full-year 2026, causing their stock to fall significantly. Investors who lost money are urged to contact the law firm to learn about potentially pursuing a claim.
BMO Capital Markets Initiates Coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY)
BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with an "outperform" rating and a $318 price target, suggesting a 39.1% upside. This positive outlook comes despite some other firms recently lowering their price targets. Alnylam Pharmaceuticals also reported strong quarterly earnings, exceeding analyst expectations with $1.84 EPS and a 66.9% year-over-year revenue increase to $1.29 billion.
ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm
Kessler Topaz Meltzer & Check, LLP has initiated an investigation into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential violations of federal securities laws after the company reported disappointing Q2 2026 financial results and lowered its full-year TTR product sales guidance by approximately $200 million. Following this announcement, Alnylam's stock price dropped over 28%. Investors who suffered financial losses are encouraged to contact KTMC for a discussion of their legal rights.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) on behalf of investors. This investigation follows Alnylam's announcement on July 30, 2026, of lowered full-year 2026 TTR product sales guidance, leading to a significant drop in its stock price. The firm encourages shareholders to participate in the investigation, noting that it operates on a contingency fee basis.
Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam cut its full-year TTR product sales guidance by approximately $200 million, leading to a stock price drop of over 28%. The firm is encouraging investors who experienced financial losses to contact them to discuss their legal rights.
SCS Capital Management LLC Invests $34.78 Million in Alnylam Pharmaceuticals, Inc. $ALNY
SCS Capital Management LLC has invested $34.78 million in Alnylam Pharmaceuticals, acquiring 115,549 shares, which represents about 0.09% of the company. Institutional investors now own 92.97% of Alnylam's stock, while analysts maintain a "Moderate Buy" rating with an average price target of $393.86, despite some recent price target reductions. The stock opened at $228.65, significantly below its one-year high.
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing
Alnylam Pharmaceuticals has experienced a significant stock sell-off due to lowered revenue guidance for its ATTR products and competition from BridgeBio. However, the article argues that the market reaction is overdone, highlighting Amvuttra's strong sales growth, a favorable competitive landscape after a rival drug's failure, and Alnylam's confident future outlook and attractive valuation. The author suggests that investors are missing the full positive story and a potential buying opportunity.
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm
Kessler Topaz Meltzer & Check, LLP is investigating Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) for potential federal securities law violations after the company announced disappointing Q2 2026 financial results. Alnylam significantly lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop over 28%. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights.
ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256
Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and a solid GF Score™ of 70/100. Insider selling activity, however, suggests a cautious sentiment.
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $256.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $316.00 to $256.00, while maintaining an "equal weight" rating. This adjustment implies a potential upside of 14.71% from the stock's previous close. Despite this reduction and similar moves by other analysts, the consensus rating for Alnylam Pharmaceuticals remains a "Moderate Buy" with an average price target of $393.86.
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test
Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, leading to significant share price pressure. Despite a "most popular narrative" suggesting the stock is 47.8% undervalued with a fair value of $434.72, this valuation relies on ambitious growth and profitability assumptions, including strong uptake of AMVUTTRA. The article questions whether these long-term assumptions remain realistic given the recent setbacks and highlights that the current P/E ratio is already high compared to the industry.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for possible violations of federal securities laws. The investigation stems from Alnylam's revised 2026 TTR product sales guidance, which led to a significant drop in its stock price on July 30, 2026. Shareholders who lost money are encouraged to contact the law firm to explore potential claims.
Alnylam Pharmaceuticals (ALNY) Cuts Guidance As Undervalued Narrative Faces A Tougher Test
Alnylam Pharmaceuticals (ALNY) recently cut its full-year 2026 TTR product sales guidance by $200 million and is under a securities law investigation, causing its stock price to drop significantly. Despite a current "undervalued" narrative with a fair value of $434.72 against its $227.12 close, this valuation relies on ambitious growth and profitability assumptions that are now being re-evaluated in light of the
Stifel Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $318
Stifel has reiterated its Buy rating on Alnylam Pharmaceuticals (ALNY.US) and maintained its target price of $318. This indicates the firm's continued confidence in the company's stock performance.
Securities Fraud Investigation Into Alnylam
Glancy Prongay Wolke & Rotter LLP has initiated a securities fraud investigation into Alnylam Pharmaceuticals, Inc. (ALNY) following a significant drop in its stock price. The investigation stems from Alnylam lowering its TTR product sales guidance for full-year 2026, leading to an $81.25 (28.35%) intraday decline in share price on July 30, 2026. The law firm is urging investors who lost money to contact them to potentially pursue claims under federal securities laws.
Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Alnylam Pharmaceuticals, Inc. (ALNY) for potential violations of federal securities laws. This follows Alnylam's announcement on July 30, 2026, where the company lowered its full-year 2026 TTR product sales guidance by approximately $200 million, leading to a significant drop in its stock price. Shareholders who incurred losses are encouraged to contact the firm to inquire about pursuing claims.
Is Alnylam’s Mixed 2026 Guidance Reset Altering The Investment Case For Alny (ALNY)?
Alnylam Pharmaceuticals reported strong Q2 2026 revenues of US$1.29 billion and net income of US$164.49 million, with H1 revenues reaching US$2.46 billion and net income at US$370.49 million. However, the company adjusted its full-year 2026 guidance, lowering net product revenue expectations while increasing collaboration and royalty income. This shift highlights a changing investment narrative, moving from pure AMVUTTRA upside to the importance of partnered programs and royalties in offsetting franchise volatility, even as analysts' long-term forecasts for 2029 remain robust.
Handelsbanken Fonder AB Sells 29,207 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Handelsbanken Fonder AB reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 21.4% in the second quarter, selling 29,207 shares and retaining 107,255 shares valued at $32.3 million. Despite this, institutional investors collectively own 92.97% of the company's stock, with several major funds increasing their positions. Alnylam Pharmaceuticals currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $396.72 against a recent share price of $221.20.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY) after the company lowered its full-year 2026 TTR product sales guidance, causing its stock price to drop significantly. The investigation encourages investors who purchased Alnylam securities to connect with the firm to assist in the process. The firm operates on a contingency fee basis for class actions.
